Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Taking aim at ALK across the blood-brain barrier.

Camidge DR.

J Thorac Oncol. 2013 Apr;8(4):389-90. doi: 10.1097/JTO.0b013e3182864e7c. No abstract available.

2.

[Notable adverse events of ALK inhibitors in patients with ALK rearranged non-small-cell lung cancer].

Tanimoto A, Yano S.

Nihon Rinsho. 2015 Feb;73 Suppl 2:256-60. Japanese. No abstract available.

PMID:
25831763
3.

Crizotinib in ALK-positive lung cancer.

Girard N.

Lancet Oncol. 2012 Oct;13(10):962-3. doi: 10.1016/S1470-2045(12)70375-3. Epub 2012 Sep 4. No abstract available.

PMID:
22954506
4.

A nice problem to have: when ALK inhibitor therapy works better than expected.

Doebele RC.

J Thorac Oncol. 2014 Apr;9(4):433-5. doi: 10.1097/JTO.0000000000000124. No abstract available.

5.

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.

Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H.

Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. doi: 10.1007/s00280-014-2578-6. Epub 2014 Sep 10.

PMID:
25205428
6.

First-line crizotinib in ALK-positive lung cancer.

Alkan A, Köksoy EB, Utkan G.

N Engl J Med. 2015 Feb 19;372(8):781-2. doi: 10.1056/NEJMc1415973#SA2. No abstract available. Erratum in: N Engl J Med. 2015 Feb 26;372(9):87.

PMID:
25693023
7.

First-line crizotinib in ALK-positive lung cancer.

Tural D, Kilickap S.

N Engl J Med. 2015 Feb 19;372(8):781. doi: 10.1056/NEJMc1415973#SA1. No abstract available.

PMID:
25693022
8.

First-line crizotinib in ALK-positive lung cancer.

Solomon BJ, Mok T.

N Engl J Med. 2015 Feb 19;372(8):782. doi: 10.1056/NEJMc1415973. No abstract available.

9.

A selective ALK inhibitor in ALK-rearranged patients.

Yang JC.

Lancet Oncol. 2013 Jun;14(7):564-5. doi: 10.1016/S1470-2045(13)70170-0. Epub 2013 Apr 30. No abstract available.

PMID:
23639469
10.

[Horizon
--interpretation of ALK-positive non-small cell lung cancer Chinese story].

Liu X.

Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):59-60. doi: 10.3779/j.issn.1009-3419.2015.02.01. Chinese. No abstract available.

11.

Hope without hype: EML4-ALK inhibition for treatment of lung cancer.

Govindan R.

Lancet Oncol. 2011 Oct;12(11):983-4. doi: 10.1016/S1470-2045(11)70253-4. Epub 2011 Sep 18. No abstract available.

PMID:
21933750
12.

[Crizotinib - molecular therapy for lung cancer].

Gröschel A, Warth A, Reinmuth N.

Pneumologie. 2013 Apr;67(4):205-8. doi: 10.1055/s-0032-1326365. Epub 2013 Apr 10. Review. German.

13.

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

Kaneda H, Okamoto I, Nakagawa K.

J Thorac Oncol. 2013 Apr;8(4):e32-3. doi: 10.1097/JTO.0b013e3182843771. No abstract available.

14.

Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.

Klempner SJ, Ou SH.

Chin Clin Oncol. 2015 Jun;4(2):20. doi: 10.3978/j.issn.2304-3865.2015.05.03. Review.

15.

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.

Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B.

Lancet Oncol. 2015 Oct;16(13):e510-21. doi: 10.1016/S1470-2045(15)00013-3. Review.

PMID:
26433824
16.

Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.

Pennell NA.

Am J Manag Care. 2012 May;18(5 Spec No. 2):SP84-7. No abstract available.

17.

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.

Shan L, Jiang P, Xu F, Zhang W, Guo L, Wu J, Zeng Y, Jiao Y, Ying J.

J Thorac Oncol. 2015 Jun;10(6):e37-9. doi: 10.1097/JTO.0000000000000467. No abstract available.

18.

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

Zhao N, Zheng SY, Yang JJ, Zhang XC, Xie Z, Xie B, Su J, Chen ZH, Chen SL, Zhang N, Lou NN, Dong S, Wu YL.

Clin Lung Cancer. 2015 Mar;16(2):e5-9. doi: 10.1016/j.cllc.2014.11.001. Epub 2014 Nov 18. Review. No abstract available.

PMID:
25496960
19.

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

Costa DB, Kobayashi S.

J Thorac Oncol. 2012 Mar;7(3):623-5. doi: 10.1097/JTO.0b013e318241daab. No abstract available.

20.

Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.

Browning ET, Weickhardt AJ, Camidge DR.

J Thorac Oncol. 2013 Mar;8(3):e21. doi: 10.1097/JTO.0b013e31827a892c. No abstract available.

Supplemental Content

Support Center